RxDoctor Payments Data
★ My doctorsLook up a doctor →

Teresa Sligh

Internal Medicine · Burbank, CANPI 1720350929

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $1,680 of the $1,785 with a category attached, or 94.1%. Pfizer accounts for 95.3% of it on its own, with 2 other manufacturers making up the rest. 2022 is the largest year on record at $1,680, more than ten times the $65 reported in 2019.

$1,785in general payments, 2019–2025

Across 5 payments — averaging $356.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$2K
  • Novo Nordisk$65
  • Kiniksa Pharmaceuticals, Ltd.$20
$4,830,959in research payments, 2019–2025

Across 471 payments — averaging $10,257 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Pfizer$1.3M
  • Hikma Pharmaceuticals USA$962K
  • AbbVie$744K
  • AstraZeneca$443K
  • Teva Pharmaceuticals USA, Inc.$334K
  • Ironwood Pharmaceuticals, Inc$206K
  • plus $812K from 17 others

What the payments were for

  • Consulting fees$1,68094%
  • Food & beverage$201%
  • Education$654%
  • Gifts$201%

General payments by program year

19
21
22

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Pfizer2$1,700
Novo Nordisk2$65
Kiniksa Pharmaceuticals, Ltd.1$20

How this compares

$1,785 in reported general payments places this provider in the 80th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California →

Other internal medicine in Burbank

See the full list for California →

Where these figures come from

Is this you, or does something look wrong? →